Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13332854 | 0.96 | SLC6A3 (0.46) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL10157188 | 0.91 | SLC6A3 (0.39) | SLC6A3SLC6A4SLC6A2CYP3A4ALDH1A1 | |
| SCHEMBL9604744 | 0.81 | SLC6A3 (0.35) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL13755345 | 0.79 | SLC6A4 (0.65) | SLC6A3SLC6A4SLC6A2CYP3A4ALOX15 | |
| SCHEMBL21239901 | 0.78 | SLC6A4 (0.50) | SLC6A3SLC6A4SLC6A2CYP3A4ALOX15 | |
| SCHEMBL871577 | 0.77 | CYP3A4 (0.70) | SLC6A3SLC6A4SLC6A2CYP3A4ALOX15 | |
| SCHEMBL25062138 | 0.75 | SLC6A3 (0.38) | SLC6A3SLC6A4SLC6A2CYP3A4ALOX15 | |
| SCHEMBL13332852 | 0.75 | SLC6A4 (0.70) | SLC6A3SLC6A4SLC6A2CYP3A4ALOX15 | |
| SCHEMBL13932847 | 0.75 | MAOB (0.41) | SLC6A3SLC6A2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL2615207 | 0.75 | SLC6A3 (0.74) | SLC6A3SLC6A4SLC6A2CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-9326973-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| US-8759337-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | US | disclosed |
| US-20120245158-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-09-27 | — | — | US | disclosed |
| US-20120232108-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-09-13 | — | — | US | disclosed |
| US-20120135980-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-05-31 | — | — | US | disclosed |
| US-20110294784-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME LLC | 2011-12-01 | — | — | US | disclosed |
| US-20100298372-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100137320-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137320-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, GSAP | SLC6A3 4321/4885SLC6A4 4298/4885SLC6A2 4201/4885 |
| US-20120232108-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | SLC6A3 4483/4885SLC6A4 4475/4885SLC6A2 4451/4885 |
| US-20110294784-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, GSAP | SLC6A3 4148/4885SLC6A4 4205/4885SLC6A2 3854/4885 |
| US-20120245158-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | SLC6A3 4483/4885SLC6A4 4475/4885SLC6A2 4451/4885 |
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | SLC6A3 3379/4885SLC6A4 3790/4885SLC6A2 3944/4885 |
| US-20120135980-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, GSAP | SLC6A3 4148/4885SLC6A4 4205/4885SLC6A2 3854/4885 |
| US-20100298372-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | SLC6A3 4521/4885SLC6A4 4547/4885SLC6A2 4438/4885 |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, EIF2AK2 | SLC6A3 3379/4885SLC6A4 3790/4885SLC6A2 3944/4885 |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | SLC6A3 3379/4885SLC6A4 3790/4885SLC6A2 3944/4885 |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | SLC6A3 3379/4885SLC6A4 3790/4885SLC6A2 3944/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | SLC6A3 3730/4885SLC6A4 4154/4885SLC6A2 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.